Patents by Inventor Linda L. Chang

Linda L. Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
    Patent number: 5776954
    Abstract: The present invention addresses substituted pyridyl pyrroles, as well as compositions containing such compounds and methods of treatment. The compounds in the present invention are glucagon antagonists and inhibitors of the biosynthesis and action of TNF-.alpha. and IL1. The compounds block the action of glucagon at its receptors and thereby decrease the levels of plasma glucose. The instant pyrroles are also inhibitors of TNF-.alpha. and IL1 and may be used as antidiabetic agents as well as other cytokine mediated diseases. Cytokine mediated diseases refers to diseases or conditions in which excessive or unregulated production of one or more cytokines occurs. Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are cytokines produced by a variety of cells, which are involved in immunoregulation and other physiological conditions, such as inflammation.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: July 7, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Stephen E. de Laszlo, Linda L. Chang, Dooseop Kim, Nathan B. Mantlo
  • Endothelin antagonists bearing pyridyl amides
    Patent number: 5559135
    Abstract: Phenoxyphenylacetic acids and derivatives of the general structural formula I ##STR1## have endothelin antagonist activity and are useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, inflammatory diseases including Raynaud's disease and asthma.
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: September 24, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Linda L. Chang, William J. Greenlee
  • Endothelin antagonists bearing 5-membered heterocyclic amides
    Patent number: 5538991
    Abstract: Phenoxyphenylacetic acids and derivatives of the general structural formula I ##STR1## have endothelin antagonist activity and are useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, inflammatory diseases including Raynaud's disease and asthma.
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: July 23, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Linda L. Chang, William J. Greenlee
  • Substituted 1,2,4-triazolin-3-one compounds bearing acidic functional groups as balanced angiotensin II antagonists
    Patent number: 5436259
    Abstract: Novel substituted 1,2,4-triazolin-3-ones of the formula (I) are useful as angiotensin II antagonists.
    Type: Grant
    Filed: November 18, 1993
    Date of Patent: July 25, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Prasun K. Chakravarty, Linda L. Chang
  • Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
    Patent number: 5411980
    Abstract: There are disclosed new substituted triazolinone, triazolinethione, and triazolinimine compounds which are useful as angiotensin II antagonists. These compounds have the general formula: ##STR1## wherein G is R.sup.
    Type: Grant
    Filed: December 21, 1992
    Date of Patent: May 2, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Linda L. Chang, Malcolm MacCoss, Prasun K. Chakravarty, William J. Greenlee, Arthur A. Patchett, Kelly Flanagan
  • Substituted triazoles as angiotensin II antagonists
    Patent number: 5336778
    Abstract: Novel substituted triazoles of the formula (I), which are useful as angiotensin II antagonists, are disclosed.
    Type: Grant
    Filed: June 22, 1992
    Date of Patent: August 9, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Christine L. Cantone, Linda L. Chang, Malcolm Maccoss, Prasun K. Chakravarty, William J. Greenlee, Arthur A. Patchett, Thomas F. Walsh
  • Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
    Patent number: 5312820
    Abstract: Carbamoyl and oxycarbonyl derivatives of biphenylmethylamines of structure I are angiotensin-II antagonists with balanced AT.sub.1 and AT.sub.2 activity useful in the treatment of hypertension and related disorders and ocular hypertension. ##STR1## where X is --O-- or --N(R.sup.7)--.
    Type: Grant
    Filed: July 17, 1992
    Date of Patent: May 17, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Linda L. Chang, William J. Greenlee, Steven M. Hutchins, Ralph A. Rivero
  • Substituted 1,2,4-triazoles bearing acidic functional groups as angiotensin II antagonists
    Patent number: 5281614
    Abstract: Novel substituted triazolinone, triazolinethione, and triazolinimine compounds of the formula I are useful as angiotensin II antagonists.
    Type: Grant
    Filed: November 2, 1992
    Date of Patent: January 25, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Prasun K. Chakravarty, Linda L. Chang, William J. Greenlee, Dooseop Kim, Nathan B. Mantlo, Arthur A. Patchett
  • Substituted pyrazoles, compositions and use
    Patent number: 5262412
    Abstract: Substituted pyrazole compounds are angiotensin II antagonists and therefore useful in the treatment of hypertension, and related cardiovascular disorders and ocular hypertension.
    Type: Grant
    Filed: March 10, 1993
    Date of Patent: November 16, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Linda L. Chang, William J. Greenlee, Steven M. Hutchins